title: Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways.
abstract: The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2), produced in lateral hypothalamic neurons, are critical regulators of feeding behavior, the reward system, and sleep/wake states. Orexin-producing neurons (orexin neurons) are regulated by various factors involved in regulation of energy homeostasis and sleep/wakefulness states. Bombesin receptor subtype 3 (BRS3) is an orphan receptor that might be implicated in energy homeostasis and is highly expressed in the hypothalamus. However, the neural pathway by which BRS3 regulates energy homeostasis is largely unknown. We examined whether BRS3 is involved in the regulation of orexin neurons. Using a calcium imaging method, we found that a selective BRS3 agonist [Ac-Phe-Trp-Ala-His-(tauBzl)-Nip-Gly-Arg-NH2] increased the intracellular calcium concentration of orexin neurons. However, intracellular recordings from slice preparations revealed that the BRS3 agonist hyperpolarized orexin neurons. The BRS3 agonist depolarized orexin neuron in the presence of tetrodotoxin. Moreover, in the presence of GABA receptor blockers, picrotoxin and CGP55845, the BRS3 agonist induced depolarization and increased firing frequency. Additionally, double-label in situ hybridization study revealed that Brs3 mRNA was expressed in almost all orexin neurons and many cells around these neurons. These findings suggest that the BRS3 agonist indirectly inhibited orexin neurons through GABAergic input and directly activated orexin neurons. Inhibition of activity of orexin neurons through BRS3 might be an important pathway for regulation of feeding and sleep/wake states. This pathway might serve as a novel target for the treatment of obesity.
authors.affiliation: Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa-shi, Ishikawa, 920-8640, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Furutani
authors.forename: Mari
authors.initials: M
authors.lastname: Hondo
authors.forename: Natsuko
authors.initials: N
authors.lastname: Tsujino
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sakurai
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D007031:Hypothalamus / Q000166:cytology / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism*; D000068797:Orexins; D018408:Patch-Clamp Techniques; D018004:Receptors, Bombesin / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D018004:Receptors, Bombesin; C107120:bombesin receptor subtype 3; D005680:gamma-Aminobutyric Acid; D002118:Calcium
references.citation: Regul Pept. 2000 Dec 22;96(1-2):45-51
references.pmid: 11102651
references.citation: Neuron. 2000 Sep;27(3):469-74
references.pmid: 11055430
references.citation: J Med Chem. 2003 May 8;46(10):1918-30
references.pmid: 12723954
references.citation: Neuroscience. 2003;120(2):309-24
references.pmid: 12890504
references.citation: Cell. 1999 Aug 6;98(3):365-76
references.pmid: 10458611
references.citation: J Endocrinol. 1999 Mar;160(3):R7-12
references.pmid: 10077743
references.citation: Biochemistry. 2002 Jul 16;41(28):8954-60
references.pmid: 12102638
references.citation: Eur J Biochem. 1992 Sep 1;208(2):405-10
references.pmid: 1325907
references.citation: Cell Metab. 2010 Feb 3;11(2):101-12
references.pmid: 20096642
references.citation: Neuron. 2003 Jun 5;38(5):701-13
references.pmid: 12797956
references.citation: Neuron. 2001 May;30(2):345-54
references.pmid: 11394998
references.citation: J Pept Sci. 2005 Mar;11(3):136-41
references.pmid: 15635635
references.citation: Genomics. 2004 Jul;84(1):139-46
references.pmid: 15203211
references.citation: J Neurosci. 2005 Aug 10;25(32):7459-69
references.pmid: 16093397
references.citation: J Pharmacol Exp Ther. 2008 Feb;324(2):463-74
references.pmid: 18006692
references.citation: Nat Med. 2000 Sep;6(9):991-7
references.pmid: 10973318
references.citation: Regul Pept. 2002 Mar 15;104(1-3):153-9
references.pmid: 11830290
references.citation: Biochem Biophys Res Commun. 2009 Sep 18;387(2):283-8
references.pmid: 19580790
references.citation: Physiol Behav. 1999 Jul;66(5):863-7
references.pmid: 10405115
references.citation: J Biol Chem. 1997 Oct 10;272(41):26062-71
references.pmid: 9325344
references.citation: Pharmacol Rev. 2008 Mar;60(1):1-42
references.pmid: 18055507
references.citation: Biochem Biophys Res Commun. 2003 Mar 28;303(1):120-9
references.pmid: 12646175
references.citation: Brain Res. 1997 Jul 11;762(1-2):165-72
references.pmid: 9262170
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12150-5
references.pmid: 16880388
references.citation: Cell. 1998 Feb 20;92(4):573-85
references.pmid: 9491897
references.citation: Nature. 1997 Nov 13;390(6656):165-9
references.pmid: 9367152
references.citation: Cell. 1999 Aug 20;98(4):437-51
references.pmid: 10481909